Artesunate (Ridsunate) is an intravenous anti-malarial drug primarily used for the initial treatment of severe malaria in adults and children. As a crucial component of severe malaria treatment regimens, its rational use must adhere to specific medication guidelines and monitoring requirements.

Precautions for the Use of Artesunate (Ridsunate)

Medication in Special Populations

Patients with hepatic impairment: Most patients with severe malaria will have a certain degree of hepatic impairment, and no dosage adjustment is required. However, there is limited experience in using this drug in patients with severe hepatic impairment (Child-Pugh score > 9), so it should be used with caution and under enhanced monitoring.

Patients with renal impairment: No dosage adjustment is needed for patients with renal impairment, including those with end-stage renal disease requiring hemodialysis.

Pediatric patients: The efficacy of artesunate in children aged 6 months and above has been established. Pharmacokinetic simulations in infants under 6 months of age show that their drug exposure is equivalent to or higher than that in older children or adults, so no dosage adjustment is required.

Pregnant women: Animal studies have shown embryotoxicity, but human data are limited. Treating severe malaria may save the lives of pregnant women and fetuses, and treatment should not be delayed due to pregnancy. During treatment, patients should be informed of potential risks, and their participation in pregnancy safety monitoring programs is encouraged.

Drug Interactions

Nevirapine or ritonavir: May reduce the plasma concentration of dihydroartemisinin (DHA), so therapeutic efficacy should be monitored.

Potent UGT inducers (e.g., rifampicin, carbamazepine, phenytoin): May reduce anti-malarial efficacy, so monitoring is required.

Hormonal contraceptives: Their efficacy may be reduced, and alternative contraceptive measures should be used during treatment and for 1 month after drug discontinuation.

Warfarin: The INR (International Normalized Ratio) value may decrease 7-10 days after treatment initiation, so close monitoring is necessary.

Monitoring for Artesunate (Ridsunate) Use

Pre-Treatment Assessment

Conduct a detailed review of the patient's medication history, with special attention to drugs that are UGT substrates.

Assess the patient's allergy history (especially a history of allergies to artemisinin derivatives).

Perform baseline tests of liver function and renal function.

Conduct pregnancy testing for women of childbearing age.

For patients using warfarin, measure the baseline INR value.

Evaluate the species of Plasmodium and the severity of malaria.

Therapeutic Efficacy Monitoring

Record the parasite clearance time and the improvement of clinical symptoms.

Monitor changes in clinical indicators such as body temperature and consciousness status.

Assess whether a transition to oral anti-malarial treatment is necessary.

Safety Monitoring

Hemolysis monitoring: Regularly test hemoglobin, reticulocytes, haptoglobin, and LDH (lactate dehydrogenase) for at least 4 weeks after treatment.

Liver function monitoring: Pay particular attention to bilirubin and transaminase levels.

Renal function monitoring: Monitor changes in creatinine levels and urine output.

Allergic reaction monitoring: Observe for manifestations such as rash, hypotension, and dyspnea.

Neurological monitoring: Evaluate the patient's consciousness status and neurological symptoms.